ArticleMolecular nutrition & food research2026
Metabolization of Flavan-3-ol Oligomers by Eggerthella lenta, a Human Gut Bacterium.
Article in Molecular nutrition & food research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Flavan-3-ols are among the most widely consumed flavonoids and have been implicated in the prevention of cardiometabolic diseases. Increasing evidence indicates that phenolic metabolites produced by the gut microbiota from flavan-3-ols contribute significantly to these effects. While some bacterial species can metabolize flavan-3-ol monomers, no isolates with activity on oligomers, i.e., procyanidins, have been reported. Since the gut microbiota is known to hydrolyze procyanidins, our aim was to identify bacteria capable of degrading them and to characterize their resulting metabolites. Through culturomic, genomic, and metabolomic approaches, we isolated novel strains of Eggerthella lenta and Flavonifractor plautii that metabolize flavan-3-ol monomers. Their activity was subsequently tested on B-type (DP 2 to 4) and A-type (DP 2) procyanidins. Only E. lenta was able to convert procyanidins, whereas F. plautii, either alone or in co-culture with E. lenta, showed no detectable activity. The reaction catalyzed by E. lenta corresponded to C-ring opening of the terminal unit of the oligomers. This work provides the first demonstration of procyanidin metabolism by a human gut bacterium. The presence and activity of E. lenta in the gut may therefore be a key determinant of the health benefits associated with flavan-3-ol-rich diets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.